{"id":"venlafaxine-ir-and-venlafaxine-xr","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Dizziness"},{"rate":"10-15","effect":"Insomnia"},{"rate":"10-15","effect":"Somnolence"},{"rate":"10-15","effect":"Sweating"},{"rate":"10-15","effect":"Sexual dysfunction"},{"rate":"5-10","effect":"Hypertension"},{"rate":"5-10","effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL1201066","moleculeType":"Small molecule","molecularWeight":"313.87"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the reuptake transporters for both serotonin and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. The IR (immediate-release) formulation provides rapid onset of action, while the XR (extended-release) formulation delivers the drug over an extended period for once-daily dosing. This mechanism is thought to restore normal mood regulation and reduce symptoms of depression and anxiety.","oneSentence":"Venlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:08.246Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Social anxiety disorder"},{"name":"Panic disorder"},{"name":"Vasomotor symptoms associated with menopause"}]},"trialDetails":[{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT01838681","phase":"PHASE3","title":"Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-06","conditions":"Major Depressive Disorder","enrollment":1986},{"nctId":"NCT02005107","phase":"PHASE4","title":"Venlafaxine PK Following Bariatric Surgery","status":"COMPLETED","sponsor":"North Dakota State University","startDate":"2013-12","conditions":"Roux en Y Gastric Bypass, Sleeve Gastrectomy","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Effexor and Effexor XR"],"phase":"marketed","status":"active","brandName":"Venlafaxine IR and Venlafaxine XR","genericName":"Venlafaxine IR and Venlafaxine XR","companyName":"North Dakota State University","companyId":"north-dakota-state-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Venlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites. Used for Major depressive disorder, Generalized anxiety disorder, Social anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}